Scientific Advisory Board
The Scientific Advisory Board has an advisory role to both the Executive Committee and the Board of Directors.
The Scientific Advisory Board is consulted on strategic subjects such as the acquisition of products for veterinary use by the Company, pharmaceutical development and the marketing and sales strategy.
Dr. Daniel Denaud has been a consultant in the field of animal health since his retirement in 2012.From 2010 to 2012, he was Vice President of Marketing and Strategic Operations at Pfizer Animal Health (Europe, Africa and the Middle East).
Between 1983 and 2010, he held a series of senior positions at Pfizer Animal Health, including Regional Director Italy / Greece, Country Director (Africa, Middle East), Marketing & Technical Director (Africa, Middle East), and finally in 2004 he was nominated as Vice-President and Head of Pfizer Animal Health France.
Daniel graduated from the Toulouse Veterinary School and obtained a master’s degree in tropical animal diseases from the Institute of Veterinary Tropical Medicine in Paris. During his career at Pfizer, he participated in the Pfizer leadership development program at Harvard University.
He also studied marketing strategy at the Columbia Business School and finance at INSEAD in Fontainebleau.
After graduating from veterinary school in Toulouse (France) in 1984, Dr. Olivry became a partner in a specialty practice in Paris. In 1991, he moved to the US for a residency in dermatology and a PhD in comparative pathology at the University of California Davis. He is board-certified by both European and American Colleges of Veterinary Dermatology.
Dr. Olivry is Professor of Immunodermatology and Assistant Department Head at the North Carolina State University College of Veterinary Medicine.
He is also Adjunct Research Associate Professor of Dermatology at the University of North Carolina-Chapel Hill School of Medicine. From 2001 to 2004, he was the Chair of the International Task Force on Canine Atopic Dermatitis, and from 2008 to 2009, President of the European College of Veterinary Dermatology.
Dr. Olivry has been recognized with the “ACVD Award for Excellence for Outstanding Contributions to Science and Education” in 2004, the “NCSU Clinician of the Year award” in 2005, the “Pfizer Award for Research Excellence at NCSU” in 2010 and the “ World Small Animal Veterinary Association (WSAVA) Hill’s Excellence in Veterinary Healthcare Award” in 2013.
Dr. Olivry has authored more than 210 peer-reviewed original articles, and he has lectured extensively all over the world to veterinary and medical audiences. His current areas of research interest are canine atopic dermatitis and the mechanism and treatment of itch in dogs.
Joël Besse has been an investor in, and an advisor of life sciences, emerging companies, for the past 25 years.
He was the Managing Director of SED Ventures (since acquired by Paul Capital), a company investing internationally in biotech and medtech startups, and a Managing Partner of Atlas Venture, heading the European Life Sciences group.
As such he led early-stage financings in multiple young companies, including listed and acquired companies Actelion Ltd. (SIX: ATLN), Newron Pharmaceuticals S.p.A. (SIX: NWRN), Nitec Pharma A.G. (NASDAQ: HZNP), Novamed Pharmaceuticals Inc. (NASDAQ:SCLN), Axovan A.G., U3 Pharma GmbH, Prestwick Pharmaceuticals Inc., Novexel S.A., Novuspharma S.p.A., and Arrow Therapeutics Ltd, generating over twelve years an annual portfolio IRR in excess of 60%.
Joël is a co-founder of medtech company CeQur S.A. and of Sigmathera SAS, a CNS drug repositioning company. He is a shareholder and advisor of Owkin, Inc. a bioinformatics startup.